S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
NASDAQ:CLNN

Clene (CLNN) Stock Price, News & Analysis

$0.42
0.00 (-0.68%)
(As of 09:51 AM ET)
Today's Range
$0.42
$0.43
50-Day Range
$0.38
$0.53
52-Week Range
$0.25
$1.22
Volume
22,349 shs
Average Volume
791,571 shs
Market Capitalization
$54.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Clene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,446.9% Upside
$6.50 Price Target
Short Interest
Healthy
0.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Clene in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.33) to ($0.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.09 out of 5 stars

Medical Sector

367th out of 939 stocks

Pharmaceutical Preparations Industry

167th out of 434 stocks

CLNN stock logo

About Clene Stock (NASDAQ:CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

CLNN Stock Price History

CLNN Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Clene's (CLNN) Buy Rating Reaffirmed at Benchmark
Clene Inc Ordinary Shares
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Breaking Down Clene: 4 Analysts Share Their Views
Clene: Q4 Earnings Insights
Clene to Present at the 36th Annual ROTH Conference
CLNN Mar 2024 1.000 put
CLNN Mar 2024 3.000 call
See More Headlines
Receive CLNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLNN
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$10.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,429.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-49,500,000.00
Net Margins
-7,569.42%
Pretax Margin
-7,569.42%

Debt

Sales & Book Value

Annual Sales
$650,000.00
Book Value
$0.10 per share

Miscellaneous

Free Float
94,268,000
Market Cap
$54.58 million
Optionable
Optionable
Beta
0.49
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Robert Etherington MBA (Age 57)
    CEO, President & Director
    Comp: $590.98k
  • Mr. Morgan R. Brown CPA (Age 56)
    M.B.A., Chief Financial Officer
    Comp: $374.05k
  • Mr. Mark G. Mortenson ESQ. (Age 66)
    Chief Science Officer
    Comp: $482.98k
  • Mr. Jerry Miraglia J.D.
    General Counsel & Corporate Secretary
  • Mr. Michael T. Hotchkin
    Chief Development Officer
  • Ms. Mary Anne Mcneil
    Head of Human Resources
  • Dr. Benjamin M. Greenberg M.D.
    M.H.S., Head of Medical

CLNN Stock Analysis - Frequently Asked Questions

Should I buy or sell Clene stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLNN shares.
View CLNN analyst ratings
or view top-rated stocks.

What is Clene's stock price target for 2024?

4 brokers have issued 1-year price objectives for Clene's stock. Their CLNN share price targets range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 1,446.9% from the stock's current price.
View analysts price targets for CLNN
or view top-rated stocks among Wall Street analysts.

How have CLNN shares performed in 2024?

Clene's stock was trading at $0.2966 at the beginning of the year. Since then, CLNN stock has increased by 41.7% and is now trading at $0.4202.
View the best growth stocks for 2024 here
.

Are investors shorting Clene?

Clene saw a decline in short interest in March. As of March 15th, there was short interest totaling 262,500 shares, a decline of 38.5% from the February 29th total of 427,100 shares. Based on an average daily trading volume, of 1,090,000 shares, the days-to-cover ratio is presently 0.2 days.
View Clene's Short Interest
.

When is Clene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our CLNN earnings forecast
.

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.13 million. Clene had a negative net margin of 7,569.42% and a negative trailing twelve-month return on equity of 253.48%.

Who are Clene's major shareholders?

Clene's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.04%), Vanguard Group Inc. (2.04%), Northern Trust Corp (0.13%), Citadel Advisors LLC (0.00%), Soltis Investment Advisors LLC (0.09%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Alison Mosca, David J Matlin, David J Matlin, General Resonance Llc, John Henry Stevens, Jonathon Gay, Robert Dee Etherington and Robert Glanzman.
View institutional ownership trends
.

How do I buy shares of Clene?

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLNN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners